Welcome to our dedicated page for Pfizer news (Ticker: PFE), a resource for investors and traders seeking the latest updates and insights on Pfizer stock.
Pfizer Inc. reports developments across its global biopharmaceutical business, including prescription medicines, vaccines, biosimilars, sterile injectables, and oncology therapies. Recurring news covers financial results and guidance, commercial portfolio changes within Biopharma, dividend declarations, capital allocation priorities, and product access initiatives for established medicines such as Eliquis.
Company updates also address clinical and regulatory activity across Pfizer's pipeline and marketed products. Recent themes include oncology data presentations, Phase 3 results for ELREXFIO in relapsed or refractory multiple myeloma, PADCEV combination regulatory activity in bladder cancer, VYNDAMAX patent litigation settlements, and shareholder meeting communications.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Pfizer Inc. (NYSE: PFE) has announced a quarterly cash dividend of $0.41 per share for the second quarter of 2023. This dividend will be payable on June 9, 2023, to shareholders recorded by the close of business on May 12, 2023. This marks the 338th consecutive quarterly dividend paid by the company, highlighting its long-standing commitment to returning value to its shareholders. Pfizer continues to focus on bringing innovative therapies to the market and maintaining a robust financial position.
AM Best has affirmed the Financial Strength Rating of A (Excellent) and the Long-Term Issuer Credit Rating of “a+” (Excellent) for Blue Whale Re Ltd., with a stable outlook. The ratings reflect Blue Whale's very strong balance sheet strength and strong operating performance, highlighting its role as the only captive insurer for org value="NYSE:PFE"Pfizer. Blue Whale insures Pfizer’s global property exposures, enhancing its enterprise risk management.
The company maintains substantial net property retentions and a diverse reinsurance program. Despite its low average loss ratios, it has moderate volatility in key metrics due to high retentions. Negative rating action could arise if Pfizer's support for Blue Whale diminishes.
Pfizer Inc. (NYSE: PFE) invites shareholders and the public to its virtual-only 2023 Annual Meeting of Shareholders on April 27, 2023, at 9:00 a.m. EDT. Shareholders can access the meeting via this link. Registration opens today, and shareholders may log in starting at 8:45 a.m. EDT. Questions can be submitted in advance until 5:00 p.m. EDT on April 25. Guests can join in listen-only mode. A replay will be available for up to one year at investors.pfizer.com.
Pfizer Inc. (NYSE:PFE) announced that the FDA has accepted for review the Supplemental New Drug Applications (sNDAs) for BRAFTOVI (encorafenib) + MEKTOVI (binimetinib) targeting metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation. The PDUFA goal date for a decision is set for Q4 2023. Currently, BRAFTOVI + MEKTOVI is approved for melanoma and colorectal cancer treatments. The sNDAs are based on the PHAROS trial results, which showed promising efficacy. However, the PR also mentions various risks and adverse effects associated with treatment, emphasizing the importance of ongoing monitoring.
org value="NYSE:PFE"Pfizer invites investors to join a conference call at 10 a.m. EDT on May 2, 2023 to discuss its First Quarter 2023 Performance Report. The call aims to provide insights into the company’s latest financial results. Interested parties can access the webcast and report via www.pfizer.com/investors, where registration details are also provided. Callers in the U.S. and Canada can dial 800-456-4352, while international participants should call 785-424-1086, using passcode “51512.” A transcript and replay will be available for 90 days after the call.